Shattuck Labs, Inc. (STTK)
NASDAQ: STTK · IEX Real-Time Price · USD
3.640
-0.350 (-8.77%)
At close: Jul 2, 2024, 4:00 PM
3.740
+0.100 (2.75%)
After-hours: Jul 2, 2024, 5:20 PM EDT
Shattuck Labs Revenue
Shattuck Labs had revenue of $2.72M in the twelve months ending March 31, 2024, with 282.93% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $1.12M with 1,856.14% year-over-year growth. In the year 2023, Shattuck Labs had annual revenue of $1.66M with 154.14% growth.
Revenue (ttm)
$2.72M
Revenue Growth
+282.93%
P/S Ratio
63.75
Revenue / Employee
$36,200
Employees
75
Market Cap
173.09M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.66M | 1.01M | 154.14% |
Dec 31, 2022 | 652.00K | -29.37M | -97.83% |
Dec 31, 2021 | 30.02M | 20.08M | 202.16% |
Dec 31, 2020 | 9.93M | 47.00K | 0.48% |
Dec 31, 2019 | 9.89M | -12.56M | -55.94% |
Dec 31, 2018 | 22.44M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Coherus BioSciences | 301.87M |
Outset Medical | 125.08M |
EDAP TMS | 65.80M |
Zevra Therapeutics | 28.01M |
bluebird bio | 21.73M |
Sera Prognostics | 206.00K |
STTK News
- 1 day ago - Shattuck Labs Announces Addition to Russell 2000® and Russell 3000® Indexes - GlobeNewsWire
- 18 days ago - Shattuck Labs Announces Updated Positive Interim Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 in Combination with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients - GlobeNewsWire
- 22 days ago - Shattuck Labs Announces Orphan Drug Designation Granted by the U.S. Food and Drug Administration (FDA) for SL-172154 for the Treatment of Acute Myeloid Leukemia (AML) - GlobeNewsWire
- 26 days ago - Shattuck Labs to Host Investor Call and Webcast on Additional Interim Data Presented at the European Hematology Association (EHA) 2024 Congress from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients - GlobeNewsWire
- 7 weeks ago - Shattuck Labs to Present Additional Data from the Phase 1B Dose Expansion Clinical Trial of SL-172154 with Azacitidine (AZA) in Frontline Higher-Risk Myelodysplastic Syndromes (HR-MDS) and TP53 mutant (TP53m) Acute Myeloid Leukemia (AML) Patients at the European Hematology Association (EHA) 2024 Congress - GlobeNewsWire
- 2 months ago - Shattuck Labs Reports First Quarter 2024 Financial Results and Recent Business Highlights - GlobeNewsWire
- 3 months ago - Shattuck Labs Announces Oral Presentation of Preclinical Data at the American Association for Cancer Research (AACR) Annual Meeting 2024 - GlobeNewsWire
- 3 months ago - Shattuck Labs Announces Participation in Upcoming 23rd Annual Needham Virtual Healthcare Conference - GlobeNewsWire